Skip Navigation Links
Centers for Disease Control and Prevention
CDC Home Search Health Topics A-Z
National Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention
   Division of Sexually Transmitted Diseases
    Program and Training Branch
STD Prevention STD Training Home Links Contact Us Glossary 
STD Prevention
Self-Study Modules
Herpes Simplex Virus (HSV)
Course Objective
Line separator
Target audience
Line separator
Continuing education
Lessons
Line separator
Epidemiology
Line separator
Pathogenesis and microbiology
Line separator
Clinical manifestations and sequelae
Line separator
Diagnostic methods
Line separator
Patient management / treatment
Line separator
Patient counseling and education
Line separator
Partner management
Line separator
Case study
Line separator
Resources
Line separator
 

Self-Study STD Module - Genital Herpes Simplex Virus (HSV) Infection

Resources

Publications

  1. Aoki FY, Tyring S, Diaz-Mitoma F, Gross G, Gao J, Hamed K. Single-day patient initiated famciclovir therapy for recurrent genital herpes: a randomized, double-blind, placebo-controlled trial. Clin Infect Dis 2006;42:8–13.
  2. Arvin AM, Prover CG:  Herpes simplex virus type 2 – a persistent problem.  New Engl J Med 1997; 337:1158-1159.
  3. Benedetti JK, Corey L, Ashley R. Recurrence rates in genital herpes after symptomatic first-episode infection. Ann Intern Med 1994;121:847–54.
  4. Bergstrom T, Vahlne A, Alestig K, et al.  Primary and recurrent herpes simplex virus type 2-induced meningitis.  J Infect Dis 1990; 162:322-330.
  5. Bodsworth NJ, Crooks RJ, Borelli S, et al. Valaciclovir versus aciclovir in patient initiated treatment of recurrent genital herpes: a randomised, double blind clinical trial. Genitourinary Med 1997;73:110–6.
  6. Brock BV, Selke S. Benedetti J, et al.  Frequency of asymptomatic shedding of herpes simplex virus in women with genital herpes.  JAMA 1990; 263:418-420.
  7. Centers for Disease Control and Prevention. Sexually Transmitted Diseases Treatment Guidelines, 2006.  MMWR 2006:55(RR-11):16-20.
  8. Chosidow O, Drouault Y, Leconte-Veyriac F, et al. Famciclovir vs. aciclovir in immunocompetent patients with recurrent genital herpes infections: a parallel-groups, randomized, double-blind clinical trial. British J Dermatol 2001;144:818–24.
  9. Conant MA, Schacker TW, Murphy RL, et al. Valaciclovir versus aciclovir for herpes simplex virus infe7ction in HIV-infected individuals: two randomized trials. Int J STD AIDS 2002;13:12–21.
  10. Corey L, Adams HG, Brown ZA, et al.  Genital herpes simplex virus infections:  clinical manifestations, course, and complications.  Ann Intern Med 1983; 98:958-972.
  11. Corey L, Spear PG.  Infections with herpes simplex viruses.  New Engl J Med 1986; 314:686-691 and 749-756.
  12. Corey L, Wald A, Patel R, et al. Once-daily valacyclovir to reduce the risk of transmission of genital herpes. N Engl J Med 2004;350:11–20.
  13. Corey L.Herpes Simplex Virus Type 2 and HIV-1: The Dialogue between the 2 organisms continues. JID 2007;195:1242-4.
  14. DeJesus E, Wald A, Warren T, et al. Valacyclovir for the suppression of recurrent genital herpes in human immunodeficiency virus-infected subjects. J Infect Dis 2003;188:1009–16.
  15. Diaz-Mitoma F, Sibbald RG, Shafran SD, Saltzman RL. Oral famciclovir for the suppression of recurrent genital herpes: a randomized controlled trial. JAMA 1998;280:887–92.
  16. Engelberg R, Carrell D, Krantz E, Corey L, Wald A. Natural history of genital herpes simplex virus type 1 infection. Sex Transmit Dis 2003;30:174–7.
  17. Faro S. A review of famciclovir in the management of genital herpes.  Infect Dis Obstet Gynecol 1998; 6(1): 38-43.
  18. Fife KH, Barbarash RA, Rudolph T et al. Valaciclovir versus acyclovir in the treatment of first-episode genital herpes infection.  Results of an international, multicenter, double-blind, randomized clinical trial.  The Valaciclovir International Herpes Simplex Virus Study Group.  Sex Transm Dis 1997 Sep; 24(8): 481-6.
  19. Fleming DT, McQuillan GM, Johnson RE et al:  Herpes simplex virus type 2 in the United States, 1976 to 1995.  N Engl J Med 1997; 337; 1105-11.
  20. Freeman EE, Weiss HA, Glynn JR, Cross PL, Whitworth JA, Hayes RJ. Herpes simplex virus 2 increases HIV acquisition in men and women: A systematic review and meta-analysis of longitudinal studies. AIDS 2006; 20:73-83.
  21. Henry RE, Wegmann JA, Hartle JE, Christopher GW. Successful oral acyclovir desensitization. Ann Allergy 1993;70:386-8.
  22. Holmes KK, Sparling PF, Mardh P-A, Lemon SM, Stamm WE, Piot P, Wasserheit JN (editors). Sexually transmitted diseases, 3rd ed. New York (NY): McGraw-Hill, 1999.
  23. Koelle DM, Benedetti J, Langenberg A, Corey L.  Asymptomatic reactivation of herpes simplex virus in women after the first episode of genital herpes.  Ann Int Med 1992; 116:443-437.
  24. Langenberg AGM, Corey L, Ashley RL et al.  A prospective study of new infections with herpes simplex virus type 1 and type 2.  N Engl J Med 1999; 341: 1432-8.
  25. Leone PA, Trottier S, Miller JM. Valacyclovir for episodic treatment of genital herpes: a shorter 3-day treatment course compared with 5-day treatment. Clin Infect Dis 2002;34:958–62.
  26. Mertz GJ, Benedetti J, Ashley R, Selke S, Corey L.  Risk factors for the sexual transmission of genital herpes.  Ann Int Med 1992; 116:197-202.
  27. Mertz GJ, Schmidt O, Jourden JL, et al.  Frequency of acquisition of first-episode genital infection with herpes simplex virus from symptomatic and asymptomatic source contacts.  Sex Trans Dis 1985; 12:33-39.
  28. Mertz GJ, Loveless MO, Levin MJ, et al. Oral famciclovir for suppression of recurrent genital herpes simplex virus infection in women. A multicenter, double-blind, placebo-controlled trial: Collaborative Famiciclovir Genital Herpes Research Group. Arch Intern Med 1997;157:343–9.
  29. Miyai T, Turner KR, Kent CK, et al. The psychosocial impact of testing individuals with no history of genital herpes for herpes simplex virus type 2. Sex Transmit Dis 2004;31:517–21.
  30. Nagot N, Ouιdraogo A, Foulongne V, et al. Reduction of HIV-1 RNA levels with therapy to suppress herpes simplex virus. N Engl J Med 2007;356(8):790-9.
  31. Patel R, Bodsworth NJ, Woolley P, et al. Valaciclovir for the suppression of recurrent genital HSV infection: a placebo controlled study of once daily therapy. Genitourinary Med 1997;73:105–9.
  32. Patel, R.  Antiviral agents for the prevention of the sexual transmission of herpes simplex in discordant couples. Curr Opin Infect Dis 2004; 17:45-48.
  33. Posavad CM, Wald A, Kuntz S, et al. Frequent reactivation of herpes simplex virus among HIV-1–infected patients treated with highly active antiretroviral therapy. J Infect Dis 2004;190:693–6.
  34. Reitano M, Tyring S, Lang W, et al.  Valaciclovir for the suppression of recurrent genital herpes simplex virus infection:  A large-scale dose range-finding study.  J Infect Dis 1998; 178: 603-610.
  35. Reyes M, Shaik NS, Graber JM, et al. Acyclovir-resistant genital herpes among persons attending sexually transmitted disease and human immunodeficiency virus clinics. Arch Intern Med 2003;163:76–80.
  36. Roberts CM, Pfister JR, Spear SJ. Increasing proportion of herpes simplex virus type 1 as a cause of genital herpes infection in college students. Sex Transmit Dis 2003;30:801–2.
  37. Romanowski B, Aoki FY, Martel AY, et al. Efficacy and safety of famciclovir for treating mucocutaneous herpes simplex infection in HIV-infected individuals. AIDS 2000;14:1211–7.
  38. Romanowski B, Valtrex HS230017 Study Group, Marina RB, Rob-erts JN. Patients’ preference of valacyclovir once-daily suppressive therapy versus twice-daily episodic therapy for recurrent genital herpes: a randomized study. Sex Transmit Dis 2003;30:226–31.
  39. Safrin S, Assaykeen T, Follansbee S, et al.  Foscarnet therapy for acyclovir-resistant mucocutaneous herpes simplex virus infection in 26 AIDS patients:  preliminary data.  J Infect Dis 1990; 161:1078-1084.
  40. Safrin S.  Treatment of acyclovir-resistant herpes simplex virus infections in patients with AIDS.  J AIDS 1992; 5(Suppl.1):S29-S32.
  41. Scott LL, Hollier LM, McIntire D, Sanchez PJ, Jackson GL, Wendel GD Jr Acyclovir suppression to prevent recurrent genital herpes at delivery. Infect Dis Obstet Gynecol 2002;10:71–7.
  42. Scoular A, Gillespie G, Carman WF. Polymerase chain reaction for diagnosis of genital herpes in a genitourinary medicine clinic. Sex Transmit Infect 2002;78:21–5.
  43. Scoular A. Using the evidence base on genital herpes: optimising the use of diagnostic tests and information provision. Sex Transmit Infect 2002;78:160–5.
  44. Sheffield JS, Hollier LM, Hill JB, Stuart GS, Wendel GD Jr Acyclovir prophylaxis to prevent herpes simplex virus recurrence at delivery: a systematic review. Obstet Gynecol 2003;102:1396–403.
  45. Sizemore JM, Lkeman F, Whitley R, Hughes A, Hook EW. The spectrum of genital herpes simplex virus infection in men attending a sexually transmitted diseases clinic. JID 2006;193:905-11.
  46. Song B, Dwyer DE, Mindel A. HSV type specific serology in sexual health clinics: use, benefits, and who gets tested. Sex Transmit Infect 2004;80:113–7.
  47. Stone KM, Reiff-Eldridge R, White AD, et al. Pregnancy outcomes following systemic prenatal acyclovir exposure: conclusions from the International Acyclovir Pregnancy Registry, 1984–1999. Birth Defects Research (Part A) 2004;70:201–7.
  48. Strick LB, Wald A, Celum C. Management of herpes simplex virus type 2 infection in HIV Type 1-infected persons. CID 2006;43:347-56.
  49. Wald A, Zeh J, Barnum G, et al:  Suppression of subclinical shedding of herpes simplex virus type 2 with acyclovir.  Ann Intern Med 1996; 124:8-15.
  50. Wald A. New therapies and prevention strategies for genital herpes.  Clin Infect Dis 1999; 28: Suppl 1:S4-13.
  51. Wald A, Langenberg AG, Link K, et al.. Effect of condoms on reducing the transmission of herpes simplex virus type 2 from men to women. JAMA 2001;27;285:3100-6.
  52. Wald A, Carrell D, Remington M, Kexel E, Zeh J, Corey L. Two-day regimen of acyclovir for treatment of recurrent genital herpes simplex virus type 2 infection. Clin Infect Dis 2002;34:944–8.
  53. Wald A, Huang M-L, Carrell D, Selke S, Corey L. Polymerase chain reaction for detection of herpes simplex virus (HSV) DNA on mucosal services: comparison with HSV isolation in cell culture. J Infect Dis 2003;188:1345–51.
  54. Wald A, Langerberg AGM, Krantz E, et al. The relationship between condom use and herpes simplex virus acquisition. Ann Intern Med 2005;143:707–13.
  55. Wald A, Krantz E, Selke S, Lairson E, Morrow RA, Zeh J. Knowledge of partners genital herpes protects against herpes simplex virus tyrpe 2 acquistion. JID 2006;194:42-52.
  56. Watts DH, Brown ZA, Money D, et al. A double-blind, randomized, placebo-controlled trial of acyclovir in late pregnancy for the reduction of herpes simplex virus shedding and cesarean delivery. Am J Obstet Gynecol 2003;188:836–43.
  57. Weinstock H, Berman S, Cates W Jr. Sexually transmitted diseases among American youth: incidence and prevalence estimates, 2000. Perspect Sex Repro Health 2004; 36(1):6-10.
  58. Whittington WL, Celum CL, Cent A, Ashley RL. Use of a glycoprotein G-based type-specific assay to detect antibodies to herpes simplex virus type 2 among persons attending sexually transmitted disease clinics. Sex Transmit Dis 2001;28:99–104.
  59. Xu F, Sternberg MR, Kottiri BJ, et al. Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States. JAMA 2006; 296:964-73.
  60. Zimet GD, Rosenthal SL, Fortenberry JD, et al. Factors predicting the acceptance of herpes simplex virus type 2 antibody testing among adolescents and young adults. Sex Transmit Dis 2004; 31:665–9.
  61. Zuckerman RA et al. Herpes simplex virus (HSV) suppression with valaciclovir reduces rectal and blood plasma HIV-1 levels in HIV-1/HSV-2-seropositive men: a randomised, double blind, placebo-controlled crossover trial. J Infect Dis 2007; 196: 1500 – 1508.

Websites and Other Resources

  1. CDC Division of STD Prevention
  2. National Network of STD/HIV Prevention Training Centers
  3. 2006 CDC STD Treatment Guidelines (including downloadable version for Palm devices)
  4. CDC-INFO
    1-800-CDC-INFO (800-232-4636)
    TTY: 1-888-232-6348
    In English, en Espaρol
  5. CDC National Prevention Information Network (NPIN)
  6. American Social Health Association (ASHA)
Page 19 of 20 BackStatusStatusNext



Page last modified: June 3, 2009
Page last reviewed: June 3, 2009
 Content Source: Division of STD Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention


STD Home | STD Index

CDC Home | Search | Health Topics A-Z

Centers for Disease Control and Prevention
 National Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention
     Division of Sexually Transmitted Diseases Prevention